Azer-cel therapy for immune-related neurological diseases
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy clinical trials.
This trial is testing an experimental cell therapy called azer-cel for people with certain autoimmune diseases that affect the nervous system. The therapy aims to reduce immune attacks on the body by targeting and removing faulty B cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these conditions: MS, NMOSD, myasthenia gravis, or CIDP
- For MS: you may be eligible if you are 18–60 and have moderate-to-severe disability (EDSS 3–6.5)
- For MS: you must have had worsening disability in the last year
- For NMOSD: you must be 18–75 and have the AQP4 antibody-positive type
- For myasthenia gravis: you must be 18–75, have the AChR or MuSK antibody, and score at least 6 on the MG-ADL daily living scale
- For CIDP: you must be 18–75 and have a moderate disability score on the INCAT scale
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This early-phase trial tests CT103A “CAR-T” cell therapy to treat certain relapsing or treatment-resistant autoimmune diseases that affect the nervous system. It aims to see whether the cells are safe and may help reduce disease activity when standard treatments haven’t controlled symptoms.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests an experimental drug called AZD0120 in adults with multiple sclerosis. It is designed for people with relapsing or progressive forms of MS who have not responded well to other treatments or have active disease.
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Hear when a new B-cell Mediated Autoimmune Disorders trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.